Novel treatment strategies in rheumatoid arthritis

The Lancet

Volumn 389, Issue 10086, 2017, Pages 2338-2348

  Burmester, Gerd R ^a   Pope, Janet E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; JANUS KINASE INHIBITOR; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

COMORBIDITY; DISEASE COURSE; DRUG SAFETY; HUMAN; MOLECULARLY TARGETED THERAPY; MORTALITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; METHOTREXATE;

EID: 85020937356     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31491-5     Document Type: Review

References (114)

1. Sokka, T, Kautiainen, H, Pincus, T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 68 (2009), 1666–1672.
2. Schumacher, HR, Klippel, JH, Koopman, WJ, Primer on the rheumatic diseases, 10th edn., 1993, Arthritis Foundation, Atlanta, GA.
3. McInnes, IB, Schett, G, Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389 (2017), 2328–2337.
4. Feist, E, Burmester, GR, Rheumatoid arthritis—clinical features. Watts, RA, Conaghan, PG, Denton, C, Foster, H, Isaacs, J, Müller-Ladner, U, (eds.) Oxford textbook of rheumatology, 4th edn., 2013, Oxford University Press, New York, NY.
5. Quinn, MA, Emery, P, Are early arthritis clinics necessary?. Best Pract Res Clin Rheumatol 19 (2005), 1–17.
6. Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
7. van Nies, JA, Krabben, A, Schoones, JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73 (2014), 861–870.
8. van Nies, JA, Tsonaka, R, Gaujoux-Viala, C, Fautrel, B, van der Helm-van Mil, AH, Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74 (2015), 806–812.
9. Weng, HH, Ranganath, VK, Khanna, D, et al. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. J Rheumatol 37 (2010), 550–557.
10. Combe, B, Landewe, R, Daien, CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2016-210602 published online Dec 15.
11. Haavardsholm, EA, Aga, AB, Olsen, IC, et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ, 354, 2016, i4205.
12. Dale, J, Purves, D, McConnachie, A, McInnes, I, Porter, D, Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res 66 (2014), 19–26.
13. Smolen, J, Breedveld, FC, Burmester, GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 (2016), 3–15.
14. GR Burmester, IB McInnes, JWJ Bijlsma, M Cutolo, Managing rheumatic and musculoskeletal diseases: past, present and future. Nat Rev Rheumatol (in press).
15. Chatzidionysiou, K, Emamikia, S, Nam, J, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 2017, 10.1136/annrheumdis-2016-210711 published online March 29.
16. Singh, JA, Saag, KG, Bridges, SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68 (2016), 1–25.
17. Smolen, JS, Landewé, R, Bijlsma, J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis, 2017, 10.1136/annrheumdis-2016-210715 published online March 6.
18. Stoffer, MA, Schoels, MM, Smolen, JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75 (2016), 16–22.
19. Gabay, C, Emery, P, van Vollenhoven, R, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
20. Burmester, GR, Lin, Y, Patel, R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76 (2017), 840–847.
21. Taylor, PC, Keystone, EC, van der Heijde, D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376 (2017), 652–662.
22. Buckley, F, Finckh, A, Huizinga, TW, Dejonckheere, F, Jansen, JP, Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21 (2015), 409–423.
23. R Fleischmann, E Mysler, S Hall, et al., Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, head-to-head, non-inferiority, randomised controlled trial. Lancet (in press).
24. Moreland, LW, O'Dell, JR, Paulus, HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64 (2010), 2824–2835.
25. O'Dell, JR, Mikuls, TR, Taylor, TH, et al. Therapies for active rheumatid arthritis after methotrexate failure. N Engl J Med 369 (2013), 307–318.
26. van Vollenhoven, RF, Ernestam, S, Geborek, P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot Trial): 1-year results of a randomized trial. Lancet 37 (2009), 459–466.
27. Verschueren, P, De Cock, D, Corluy, L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74 (2015), 27–34.
28. Katchamart, W, Johnson, S, Lin, HJ, Phumethum, V, Salliot, C, Bombarider, C, Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62 (2010), 1128–1143.
29. Bally, M, Dendukuri, N, Rich, B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ, 357, 2017, j1909.
30. Tanaka, Y, Hirata, S, Saleem, B, Emery, P, Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 31 (2013), S22–S27.
31. Hazlewood, GS, Barnabe, C, Tomlinson, G, Marshall, D, Devoe, DJ, Bombardier, C, Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev, 8, 2016, CD010227.
32. Hazlewood, GS, Barnabe, C, Tomlinson, G, Marshall, D, Devoe, D, Bombardier, C, Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ, 353, 2016, i1777.
33. Lee, EB, Fleischmann, R, Hall, S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
34. Fleischmann, R, Schiff, M, van der Heijde, D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69 (2016), 506–517.
35. Burmester, GR, Rigby, WF, van Vollenhoven, RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomized controlled trial. Ann Rheum Dis 75 (2016), 1081–1091.
36. Bijlsma, JW, Welsing, PMJ, Woodworth, TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multi-centre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 (2016), 343–355.
37. St Clair, EW, van der Heijde, DM, Smolen, JS, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004), 3432–3443.
38. Breedveld, FC, Weisman, MH, Kavanaugh, AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006), 26–37.
39. Emery, P, Breedveld, FC, Hall, S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 (2008), 375–382.
40. Emery, P, Bingham, CO III, Burmester, GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 76 (2017), 96–104.
41. Emery, P, Fleischmann, RM, Moreland, LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60 (2009), 2272–2283.
42. Westhovens, R, Robles, M, Ximenes, AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68 (2009), 1870–1877.
43. Emery, P, Burmester, GR, Bykerk, VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74 (2015), 19–26.
44. Tak, PP, Rigby, WF, Rubbert-Roth, A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70 (2011), 39–46.
45. Felson, DT, Anderson, JJ, Boers, M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995), 727–735.
46. Smolen, JS, Emery, P, Fleischmann, R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet 383 (2014), 321–332.
47. Fleischmann, R, Tongbram, V, van Vollenhoven, R, et al. A systematic review and network meta-analysis of the efficacy and safety of tumor necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open, 3, 2017, e000371.
48. Detert, J, Bastian, H, Listing, J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72 (2013), 844–850.
49. Emamikia, S, Arkema, EV, Györi, N, et al. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. RMD Open, 2, 2016, e000323.
50. Tanaka, Y, Yamanaka, H, Ishiguro, N, et al. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Res Ther, 19, 2017, 56.
51. Smolen, JS, Burmester, GR, Combe, B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 388 (2016), 2763–2774.
52. van Vollenhoven, RF, Fleischmann, R, Cohen, S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367 (2012), 508–519.
53. Schiff, M, Keiserman, M, Codding, C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67 (2008), 1096–1103.
54. Weinblatt, ME, Schiff, M, Valente, R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65 (2013), 28–38.
55. Louder, AM, Singh, A, Saverno, K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 9 (2016), 84–93.
56. Rémy, A, Avouac, J, Gossec, L, Combe, B, Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29 (2011), 96–103.
57. Schett, G, Tohidast-Akrad, M, Smolen, JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43 (2000), 2501–2512.
58. Genovese, MC, Inhibition of p38: has the fat lady sung?. Arthritis Rheum 60 (2009), 317–320.
59. Heinrich, PC, Behrmann, I, Muller-Newen, G, Schaper, F, Graeve, L, Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem J 334 (1998), 297–314.
60. Yamaoka, K, Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32 (2016), 29–33.
61. European Medicines Agency. Summary of opinion (initial authorisation) Xeljanz tofacitinib, 2017 http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004214/WC500220221.pdf (accessed April 9, 2017).
62. European Medicines Agency, Summary of opinion (initial authorisation) Olumiant baricitinib. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004085/WC500218183.pdf (accessed April 9, 2017).
63. Fleischmann, R, Schiff, M, van der Heijde, D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69 (2017), 506–517.
64. Burmester, GR, Blanco, R, Charles-Schoeman, C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
65. Genovese, MC, Kremer, J, Zamani, O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374 (2016), 1243–1252.
66. Yamaoka, K, Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster. Drug Saf 39 (2016), 823–840.
67. Curtis, JR, Xie, F, Yun, H, Bernatsky, S, Winthrop, KL, Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1843–1847.
68. Cohen, SB, Tanaka, Y, Mariette, X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis, 2017, 10.1136/annrheumdis-2016-210457 published online Jan 31.
69. Pope, J, Keystone, E, Jamal, S, et al. Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, longterm extension studies up to 7 years. Annual European Congress of Rheumatology, 2016 London; June 8–June 11, Thu0169.
70. European Medicines Agency Biosimilar medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp (accessed April 9, 2017).
71. European Medicines Agency, Remsima infliximab. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124 (accessed April 9, 2017).
72. European Medicines Agency, Benepali etanercept. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004007/human_med_001944.jsp&mid=WC0b01ac058001d124 (accessed April 9, 2017).
73. Food and Drug Administration. Information for consumers (biosimilars)., 2015 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm (accessed April 9, 2017).
74. Chingcuanco, F, Segal, JB, Kim, SC, Alexander, GC, Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: a systematic review. Ann Intern Med 165 (2016), 565–574.
75. Dörner, T, Strand, V, Cornes, P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 75 (2016), 974–982.
76. Jørgensen, KK, Olsen, IC, Goll, GL, et al., NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet, 2017, 10.1016/S0140-6736(17)30068-5 published online May 11.
77. Cohen, JP, Abigail, E, Felix, AE, Kim Riggs, K, Gupta, A, Barriers to market uptake of biosimilars in the US. GaBI J 3 (2014), 108–115.
78. Canadian Rheumatology Association. Canadian Rheumatology Association Position Statement on Biosimilars and Innovator Molecules (Biological disease modifying anti-rheumatic drugs (DMARDs)), May 10, 2017 https://rheum.ca/images/documents/Canadian_Position_Paper_on_Biosimilars_.pdf (accessed May 25, 2017).
79. Ramiro, S, Sepriano, A, Chatzidionysiou, K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis, 2017, 10.1136/annrheumdis-2016-210708 published online March 15.
80. van Walsem, A, Pandhi, S, Nixon, RM, Guyot, P, Karabis, A, Moore, RA, Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther, 17, 2015, 66.
81. Ravindran, V, Rachapalli, S, Choy, EH, Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology 48 (2009), 807–811.
82. Thompson, AE, Rieder, SW, Pope, JE, Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63 (2011), 1479–1485.
83. Bongartz, T, Sutton, AJ, Sweeting, MJ, Buchan, I, Matteson, EL, Montori, V, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006), 2275–2285.
84. Strangfeld, A, Hierse, F, Rau, R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in German biologics register RABBIT. Arthritis Res Ther, 12, 2010, R5.
85. Mercer, LK, Askling, J, Raaschou, P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 76 (2017), 386–391.
86. Gabay, C, Riek, M, Scherer, A, Finckh, A, SCQM collaborating physicians. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Qualifty Management Registry. Rheumatology 54 (2015), 1664–1672.
87. Pope, JE, Haraoui, B, Thorne, JC, et al. The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 73 (2014), 2144–2151.
88. Teitsma, XM, Marijnissen, AK, Bijlsma, JW, Lafeber, FP, Jacobs, JW, Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther, 18, 2016, 211.
89. Porter, D, van Melckebeke, J, Dale, J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388 (2016), 239–247.
90. Mankia, K, Emery, P, A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals. Curr Opin Rheumatol 28 (2016), 260–266.
91. Van Dongen, H, Van Aken, J, Lard, LR, et al. Efficacy of methotrexate in treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56 (2007), 1424–1432.
92. van Aken, J, Heimans, L, Gillet-van Dongen, H, et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 73 (2014), 396–400.
93. Marzo-Ortega, H, Green, MJ, Keenan, AM, Wakefield, RJ, Proudman, S, Emery, P, A randomized controlled trial of early intervention with intraarticular cortico-steroids followed by sulfasalazine versus conservative treatment in early oligo-arthritis. Arthritis Rheum 57 (2007), 154–160.
94. Saleem, B, Mackie, S, Quinn, M, et al. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?. Ann Rheum Dis 67 (2008), 1178–1180.
95. Nam, JL, Villeneuve, E, Hensor, EM, et al. A randomized controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis 73 (2014), 1027–1036.
96. Buch, MH, Hensor, EM, Rakieh, C, et al. Abatacept reduces disease activity and ultrasound popwer Doppler in ACPA-neagative undifferentiated arthritis: a proof-of-concept clinical and imaging study. Rheumatology 56 (2017), 58–67.
97. Gerlag, DM, Safy, M, Maijer, KI, et al. A single infusion of rituximab delays the onset of arthritis in subjects at high risk of developing RA. American College of Rheumatology Annual Meeting, Nov 11–Nov 16, 2016, 3028 Washington DC.
98. Bos, WH, Dijkmans, BA, Boers, M, van de Stadt, RJ, van Schaardenburg, D, Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis 69 (2010), 571–574.
99. Verstappen, SM, McCoy, MJ, Roberts, C, et al. Beneficial effects of a 3-week course of intramuscular glucorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 69 (2010), 503–509.
100. Machold, KP, Landewe, R, Smolen, JS, et al. The stop arthritis very early (SAVE) trial, an international multicenter, randomized, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 69 (2010), 495–502.
101. Nam, JL, Hensor, EM, Hunt, L, et al. Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. Ann Rheum Dis 75 (2016), 2060–2067.
102. Tedeschi, SK, Cui, J, Arkema, EV, et al. Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: a nested case-control study of women in the Nurses' Health Studies. Semin Arthritis Rheum, 2016, 10.1016/j.semarthrit.2016.09.001 published online Sept 13, 2016.
103. Gerlag, DM, Norris, JM, Tak, PP, Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology 55 (2016), 607–614.
104. Dougados, M, Soubrier, M, Antunez, A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73 (2014), 62–68.
105. Hitchon, C, Boire, G, Haraoui, B, et al. Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. Rheumatology 55 (2016), 1751–1762.
106. Elnady, BM, Kamal, NM, Shaker, RH, et al. Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases. Medicine, 95, 2016, e4336.
107. Roubille, C, Richer, V, Starnino, T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol 42 (2015), 1767–1780.
108. Bartlett, SJ, Schieir, O, Andersen, K, et al. Smoking and excess weight attenuate rate of improvement over first 3 years in early RA. American College of Rheumatology Annual Meeting, Nov 11–Nov 16, 2016, 3068 Washington DC.
109. Zink, A, Manger, B, Kaufmann, J, et al. Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 73 (2014), 1673–1676.
110. Roubille, C, Richer, V, Starnino, T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74 (2015), 480–489.
111. Meissner, Y, Zink, A, Kekow, J, et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther, 18, 2016, 183.
112. Giles, JT, Sattar, N, Gabriel, SE, et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. American College of Rheumatology Annual Meeting, Nov 11–Nov 16, 2016, 3L Washington DC.
113. Widdifield, J, Bernatsky, S, Paterson, JM, et al. Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. Arthritis Care Res 67 (2015), 1047–1053.
114. Zhang, Y, Lu, N, Peloquin, C, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis 76 (2017), 408–413.